This study sought to evaluate whether there were differences in survival between patients with prostate cancer – stratified into high risk and very high risk groups – who were treated with radiotherapy and androgen deprivation.
Men with prostate cancer with positive margins, extraprostatic extension, positive lymph nodes, high prostate?specific antigen, or high Gleason Score are at high risk of recurrence following primary therapy. Androgen deprivation therapy...
Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment...
Men with locally advanced Prostate Cancer and who receive radiotherapy (RT) on top of their androgen deprivation therapy (ADT) using...
Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
Background: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances.
The purpose of this study is to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by...
Chronic spontaneous urticaria, formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is more common than previously thought.
Containing relevant Learning Zones, guidelines, trials and news.
New late-breaking data from the pivotal Phase III ARASENS trial confirm consistent overall survival (OS) benefits of darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC), in pre-specified subgroups based on extent of metastatic spread (bone or visceral metastases) and alkaline phosphatase (ALP) value ( less than or greater than upper limit of normal [ULN] at study entry), compared to a current standard of care, ADT plus docetaxel. Adverse event (AE) rates were similar in both treatment arms.